中国肺癌杂志2012，Vol.15Issue(4)：208-212,5.DOI:10.3779/j.issn.1009-3419.2012.04.03
紫杉醇脂质体联合顺铂方案一线治疗晚期非小细胞肺癌的临床随机对照研究
A Randomized Trial of Liposomal Paclitaxel plus Cisplatin as First-line Therapy for Advanced Non-small Cell Lung Cancer
杨新杰 1张卉 1农靖颖 1王敬慧 1李曦 1张权 1王群慧 1高远 1张树才1
作者信息
- 1. 101149 北京,首都医科大学附属北京胸科医院肿瘤内科
- 折叠
摘要
Abstract
Background and objective Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced non-small cell lung cancer (NSCLC). In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel plus cisplatin (LP) with those of TP as first-line treatments for advanced NSCLC. Methods A total of 100 patients were randomly selected to be treated with liposomal paclitaxel or paclitaxel at a dose of ISO mg/m2 on day 1 plus cisplatin at a dose of 75 mg/m2 on days 1 and 2 per cycle every 21 days. Results All 100 patients were eligible. The median progression free survival was 5.1 months vs 4.2 months, the median OS was 9.0 months vs 9.3 months, and RR was 26% vs 24% in the LP and TP arms, respectively. No significant difference was observed (P=0.110,0.342 and 0.890, respectively). There was no significant difference between grades 3 and 4 toxicity of the arms (P>0.05). Peripheral neuritis observed in the LP arm was significantly lower than that in the TP arm (8% vs 28%), and the difference was statistically significant (P=0.030). Conclusion The effects of LP and TP as first-line therapies for NSCLC are similar. However, peripheral neuritis in the LP arm is significantly lower than in the TP arm.关键词
脂质体/紫杉醇/肺肿瘤/临床研究/化疗Key words
Liposome/ Paclitaxel/ Lung neoplasms/ Clinical trial/ Chemotherapy分类
医药卫生引用本文复制引用
杨新杰,张卉,农靖颖,王敬慧,李曦,张权,王群慧,高远,张树才..紫杉醇脂质体联合顺铂方案一线治疗晚期非小细胞肺癌的临床随机对照研究[J].中国肺癌杂志,2012,15(4):208-212,5.
